1.1Fluorine at the RA position
A single fluorine atom forms a bond to the scaffold at the RA position. The bond introduces a local dipole without adding a rotatable bond.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A single fluorine atom forms a bond to the scaffold at the RA position. The bond introduces a local dipole without adding a rotatable bond.
The two scaffold fragments attach to opposite bridgehead carbons of the cage. Three methylene bridges hold the attachment vectors along a common axis.
Each fragment bonds to one carbon of a carbon–carbon triple bond. The two sp-hybridized carbons hold the attachment bonds along a common axis.
The scaffold bonds directly to the carbonyl carbon of —C(═O)NH2. The carbonyl oxygen accepts hydrogen bonds, and the amide NH groups donate them.
The scaffold bonds directly to the carbon of —C≡N. The triple bond gives the substituent a linear geometry, and the terminal nitrogen acts as a hydrogen-bond acceptor.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A characterized LPA1 inhibitor containing the two-ring arrangement serves as the inhibition control in a research assay kit. The kit supplies single-use inhibitor aliquots, a matching vehicle, and a lysophosphatidic acid challenge solution. Each assay plate compares agonist-stimulated wells containing the inhibitor with agonist-stimulated wells containing vehicle to measure the assay response range.
A 1H-tetrazol-5-yl group replaces the carboxyl group at Q. The tetrazole attaches through its carbon atom to the scaffold atom that bears the carboxyl group in the reference compound. A matched pair uses the same rings, linker, and remaining substituents, and an LPA1 signaling assay measures the concentration-response curve of each compound.
A methylene ether segment, —CH₂O—, replaces a carbamate at X. The methylene end attaches to the scaffold atom that connects to the methylene of the reference carbamate, and the oxygen end attaches to the opposite scaffold atom. A matched pair retains the same rings and Q group for comparison in an LPA1 signaling assay.
A three-member compound series uses one, two, or three methylene units immediately before the carbamate nitrogen in X. The rings, Q group, carbamate orientation, and nitrogen substituent stay fixed across the series. Each member runs in a 10-point, threefold dilution series against a fixed lysophosphatidic acid challenge in cells expressing LPA1.
A two-channel microfluidic device holds lung epithelial cells on one side of a porous membrane and lung fibroblasts in a collagen matrix on the other. The fibroblast-side perfusate delivers lysophosphatidic acid with either a two-ring LPA1 inhibitor or matching vehicle, and parallel channels receive vehicle without agonist to establish baseline response. Imaging measures fibroblast alpha-smooth muscle actin and collagen deposition after exposure.
A liquid handler dispenses scaffold variants across a multiwell plate containing cells that express LPA1 and a calcium-sensitive fluorescent dye. A fluorescence reader records signals before and after automated addition of a fixed lysophosphatidic acid concentration. Software normalizes peak responses to vehicle-treated wells with and without agonist, fits concentration-response curves, and reports half-maximal inhibitory concentrations when the measured responses bracket the midpoint.
R3 is cyclohexyl, a saturated six-carbon ring attached through one ring carbon. The ring adopts chair conformations.
RE is 4-cyanophenyl, attached through carbon 1 of the benzene ring. A single —C≡N group bonds through its carbon to ring carbon 4.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
If B is cyclic it is selected from phenyl and a six-membered heteroaromatic ring containing one, two, or three nitrogen atoms, a six-membered ring or a six-membered bridged or spiro-fused ring containing none, one, or two heteroatoms independently selected from N, O, and S, a five-membered heteroaromatic ring containing one, two, or three heteroatoms independently selected from N, O, and S, a five-membered ring containing none, one, or two heteroatoms independently selected fA · US 9,932,326 B2 · ¶ 14
A, B, and C are each the same or different carbocyclic aryl or heteroaromatic groups (e.g., C6-14 carbocyclic aryl or heteroaromatic group having from 5 to 14 atoms, including 1-4 heteroatoms selected from O, S, and N, in the heteroaromatic ring system), each of which may be optionally substituted.B · US 10,179,778 B2 · ¶ 34
A is selected from phenyl and six-membered heteroaromatic rings containing one, two, or three nitrogen atoms;A · US 9,932,326 B2 · ¶ 12
R is —(CX′X″)nC(═O)OR, wherein n is a positive integer, each X′ and X″ is independently a hydrogen or non-hydrogen substituent, and R′ is a non-hydrogen substituent; each T, each T′ and each T″ are the same or different non-hydrogen substituent, wherein either of T and T″ or T and T′ are capable of joining to form a ring; n, n′ and n″ are each independently 0, 1, 2, 3 or 4;B · US 10,179,778 B2 · claim 7
each R1 and R1′ are independently present or absent if present are independently selected from hydroxy, hydroxyalkyl, alkoxy(C1-6), alkoxyalkyl(C2-8), alkoxycarbonyl, alkyl(C1-8), arylalkoxycarbonyl, lower alkenyl (C2-6), lower alkynyl (C2-6), carboxy, halogen (F, Cl, Br, I), CF3, haloalkyl, N3, CN, N(R′)2, SR′, OCOR′, N(COR′)R′, N(COR′)COR′, SCOR′, S(O)2NR′2, S(O)2R′.A · US 9,932,326 B2 · ¶ 37
R8 and R9, together with the carbon atom to which they are attached, form a five- or six-membered saturated ring optionally containing one or two heteroatoms selected from NRz, O, and S; wherein Rz is selected from hydrogen and alkyl;A · US 9,932,326 B2 · ¶ 56
R14 and R14′ are independently selected from halogen (F, Cl, Br, I), CF3, hydroxy, alkoxy (C1-6), aryl, 5-membered heteroaryl, lower alkyl (C1-6) or halo substituted aryl, aryl or halo substituted 5-membered heteroaryl, cyano, alkynyl (C2-6), alkoxyalkyl (C3-6), alkoxycarbonylalkyl, alkyl, arylalkoxycarbonyl, carboxy, haloalkyl, heterocyclylalkyl, hydroxyalkyl; andA · US 9,932,326 B2 · ¶ 100
each R10 and R11 are independently selected from H, alkylcarboxy amino, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylamino, alkylguanasyl, alkylaryl, aryl, arylalkenyl, arylalkoxy, arylalkyl, aryloxyalkyl, cycloalkyl, cycloakylamino, (cycloalkyl)alkenyl, (cycloalkyl)alkyl, cycloalkyloxyalkyl, haloalkyl, alkylheterocyclyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkoxy, heterocyclylalkyl, heterocyclyloxyalkyl, and hydrA · US 9,932,326 B2 · ¶ 30
R14 and R14′ are, independently, H, halogen, hydroxy, C1-6 alkoxy, aryl, 5-membered heteroaryl, C1-6 alkyl or halo substituted aryl, aryl or halo substituted 5-membered heteroaryl, cyano, C2-6 alkynyl, C3-6 alkoxyalkyl, alkoxycarbonylalkyl, heterocyclylalkyl, or hydroxyalkyl; and R15 and R15′ are, independently, hydrogen, C2-6 alkoxy, C3-6 alkoxyalkyl, alkoxycarbonyl, carbonylalkyl, carbonyl aryl, C1-6 alkyl, heterocyclylalkyl, or C2-6 hydroxyalkyl, Z is C1-6 alkyl, alkenyl,A · US 9,932,326 B2 · claim 1
An empty cell means only that no passage was reproduced there.
Therefore, there is an urgent need for new HCV drugs.A · US 9,932,326 B2 · ¶ 3
The present invention provides compounds, methods and compositions for treating or preventing HCV infection in a host.A · US 9,932,326 B2 · ¶ 7
However for many other applications, the need exists for new photoresists that can provide highly resolved images of submicron dimension.B · US 10,179,778 B2 · ¶ 3
We have now discovered new acid generators and photoresist compositions that comprise one or more of such acid generators.B · US 10,179,778 B2 · ¶ 6
patent.fyi, US 2026/0356824 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356824/, SHA-256 dd2eb4ff8827b59157be054ddc8d3751fb93e64c74ebbfa25c11e68a8d97b135